Syneos Health

Syneos Health, Inc. engages in the provision of outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded in 1998 and is headquartered in Morrisville, NC.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Syneos Health reports mixed Q4 results, focuses on growth strategies

Syneos Health's Q4 performance showed mixed results with revenue decline but growth on a constant currency basis. The company is focused on enhancing its operating model, customer engagement, and winning new business opportunities.
Challenges include evaluating spending by large pharma customers and the need for cost structure realignment. However, opportunities lie in engaging with analysts, driving cost savings, and expecting larger pharma awards in 2023.
Overall, Syneos Health remains confident in its strategy, investments, and ability to drive growth in Clinical. The company is navigating challenges while leveraging strengths in customer relationships and value-based pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Let's see if Syneos Health (SYNH) stock is a good choice for value-oriented investors right now from multiple angles.

Is Syneos Health (SYNH) a Good Value Investor Stock Now?

Syneos Health reduced its 2020 guidance but boosted its EBITDA margin guidance.

Syneos Health: An Impressive Long-Term Guidance Makes It A Buy

GREENWICH, Conn.--(BUSINESS WIRE)--Amulet Capital Partners Completes the Sale of Synteract to Syneos Health

Amulet Capital Partners Completes the Sale of Synteract to Syneos Health

MORRISVILLE, N.C., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it has completed the previously announced acquisition of Synteract, a leading full-service CRO focused on the rapidly growing, emerging biopharma segment.

Syneos Health Completes Acquisition of Synteract

Unique Product Development Model Delivers Accelerated Growth

Syneos Health to Outline Value Creation Plan at 2020 Analyst and Investor Event

VBI Vaccines

CAMBRIDGE, Mass. & MORRISVILLE, N.C.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, and Syneos Health (Nasdaq: SYNH), the leading Contract Commercialization Organization (CCO) and the longest-tenured U.S. provider of outsourced sales teams, today announced a partnership for the commercialization of VBI's 3-antigen prophylactic hepatitis B (HBV) vaccine in the United States, Europe,

 VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine

Combination Offers Customers Access to Largest U.S. Oncology Real World Data Source and Best-in-Class Product Development Expertise for Faster, Smarter and More Patient-Centric Clinical Trials Combination Offers Customers Access to Largest U.S. Oncology Real World Data Source and Best-in-Class Product Development Expertise for Faster, Smarter and More Patient-Centric Clinical Trials

Syneos Health and ConcertAI Announce Strategic Collaboration to Accelerate the Use of Real World Evidence and AI to Advance Oncology Research

Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery in the Clinical Solutions segment and strategic partnerships.

Here's Why You Should Invest in Syneos Health (SYNH) Now

MORRISVILLE, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced the completion of the previously announced offering of $600.0 million aggregate principal amount of 3.625% senior notes due 2029 (the “Notes”). The Notes are guaranteed, jointly and severally, on a senior unsecured basis, by certain of the Company's subsidiaries.

Syneos Health Announces Closing of Offering of $600.0 Million of Senior Notes Due 2029

MORRISVILLE, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced the upsizing and pricing of an offering of $600.0 million aggregate principal amount of 3.625% senior notes due 2029 (the “Notes”), an upsize of $100.0 million over the amount previously announced. The Notes were priced at par value and will bear an interest rate of 3.625% per annum. The Notes are being offered in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Notes will be guaranteed, jointly and severally, on a senior unsecured basis, by certain of the Company's subsidiaries. Syneos Health expects to close the offering of the Notes on November 24, 2020, subject to the satisfaction of customary closing conditions.

Syneos Health Announces Upsizing and Pricing of Offering of $600.0 Million of Senior Notes Due 2029

MORRISVILLE, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced it commenced an offering of $500.0 million aggregate principal amount of senior notes (the “Notes”) in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Notes will be guaranteed, jointly and severally, on a senior unsecured basis, by certain of the Company's subsidiaries.

Syneos Health Announces Senior Notes Offering

MORRISVILLE, N.C., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Larry A. Pickett, Jr. as Chief Information & Digital Officer. Pickett will lead the global Business Technology team, oversee the Company's Dynamic Assembly open architecture technology network and manage the creation of new technology and data-enabled products.

Syneos Health Names Larry A. Pickett Jr. Chief Information & Digital Officer

MORRISVILLE, N.C., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), will host an Analyst and Investor Event on Tuesday, December 8, 2020, from 9:00 a.m. to approximately 11:30 a.m. EST.

Syneos Health to Host Virtual Analyst and Investor Event on December 8, 2020

Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.

Syneos Health (SYNH) Q3 Earnings Top Estimates, Margins Up

Syneos Health, Inc. (SYNH) CEO Alistair Macdonald on Q3 2020 Results - Earnings Call Transcript

  Shares of Syneos Health (NASDAQ:SYNH) moved higher by 3.2% in pre-market trading after the company reported Q3 results.

Syneos Health: Q3 Earnings Insights

Syneos Health (SYNH) delivered earnings and revenue surprises of 15.56% and -1.92%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Tops Q3 Earnings Estimates

GREENWICH, Conn.--(BUSINESS WIRE)--Amulet Capital Backed Synteract To Be Acquired by Syneos Health

Amulet Capital Backed Synteract To Be Acquired by Syneos Health

Syneos Health Reports Third Quarter 2020 Results

Combination Enhances Syneos Health's Industry-Leading Position Across Fast-Growing Small to Mid-Sized Category Combination Enhances Syneos Health's Industry-Leading Position Across Fast-Growing Small to Mid-Sized Category

Syneos Health to Acquire Synteract, a Top CRO Provider to Emerging Biopharma

Integrating Intelligence Across Channels, Technologies and Content Achieves Greater Precision, Efficiency and Effectiveness Integrating Intelligence Across Channels, Technologies and Content Achieves Greater Precision, Efficiency and Effectiveness

Syneos Health® Launches Kinetic™ Omnichannel Capability to Accelerate Modern Customer Engagement

Company Ranks Highest Among Biopharmaceutical Outsourcing Organizations Company Ranks Highest Among Biopharmaceutical Outsourcing Organizations

Syneos Health Named to Forbes 2020 List of World's Best Employers

MORRISVILLE, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it was awarded the Society for Clinical Research Sites (SCRS) Ea g le Award, sweeping the CRO category for the fourth consecutive year. Presented at SCRS’s Global Site Solutions Summit, the award recognizes the CRO that best exemplifies a site-focused approach to clinical trial management, demonstrating outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession through strong site partnerships.

Syneos Health Wins Society for Clinical Research Sites Eagle Award for Fourth Consecutive Year

MORRISVILLE, N.C., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2020 financial results on Thursday, October 29, 2020, prior to its earnings call at 8:00 a.m. ET.

Syneos Health Schedules Third Quarter 2020 Earnings Call for Thursday, October 29, 2020

Syneos Health's (SYNH) over 70% of clinical businesses comprise essential therapeutic areas that are experiencing reduced impacts of coronavirus outbreak.

News for Syneos Health Stock (SYNH)